What is Boston Scien Cp's earnings per share (EPS)?

Boston Scien Cp (BSX) reported diluted earnings per share of $1.94 for fiscal year 2025. This represents a 55.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Boston Scien Cp Financials

BSX

FY2025 annual

Revenue $20.1B +19.9% YoY

Net Income $2.9B +56.7% YoY

EPS (Diluted) $1.94 +55.2% YoY

Free Cash Flow $3.7B +38.3% YoY

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Boston Scien Cp (BSX) reported $20.1B in revenue for fiscal year 2025, up 19.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BSX FY2025 2026-05-01

Stable gross margins let Boston Scientific turn added revenue into faster profit and cash generation without heavy reinvestment.

From FY2023 to FY2025, free cash flow climbed from $1.8B to $3.7B, showing that the recent earnings lift is arriving as spendable cash rather than remaining trapped in the accounting line. Because gross margin stayed near 69.0% and FY2025 capex was only $876M, that improvement looks like a business whose incremental sales are dropping into an already efficient operating base rather than being consumed by manufacturing or upkeep.

The balance sheet is acquisition-shaped: goodwill reached $18.3B, about 41.9% of assets, so a large share of reported value reflects past dealmaking rather than hard operating assets. What offsets that is liquidity recovery, with cash back to $2.0B and the current ratio at 1.6x, giving the company more room to absorb working-capital needs than it had a year earlier.

The most telling margin pattern is below gross profit: gross margin held near 69.0% while operating margin reached 18.0%. That usually signals better absorption of selling and development costs as scale builds, not simply cheaper production, especially since R&D still consumed $2.1B in FY2025.

Financial Health Signals

Financial Health Score 64/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Boston Scien Cp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Boston Scien Cp has an operating margin of 18.0%, meaning the company retains $18 of operating profit per $100 of revenue. This strong profitability earns a score of 81/100, reflecting efficient cost management and pricing power. This is up from 15.5% the prior year.

Growth

Boston Scien Cp's revenue surged 19.9% year-over-year to $20.1B, reflecting rapid business expansion. This strong growth earns a score of 80/100.

Leverage

Boston Scien Cp has a moderate D/E ratio of 0.46. This balance of debt and equity financing earns a leverage score of 32/100.

Liquidity

Boston Scien Cp's current ratio of 1.62 indicates adequate short-term liquidity, earning a score of 45/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Boston Scien Cp converts 18.2% of revenue into free cash flow ($3.7B). This strong cash generation earns a score of 81/100.

Returns

Boston Scien Cp earns a strong 11.9% return on equity (ROE), meaning it generates $12 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 66/100. This is up from 8.5% the prior year.

Altman Z-Score Safe

3.33

Boston Scien Cp scores 3.33, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($75.4B) relative to total liabilities ($19.4B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Boston Scien Cp passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.57x

For every $1 of reported earnings, Boston Scien Cp generates $1.57 in operating cash flow ($4.5B OCF vs $2.9B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

10.35x

Boston Scien Cp earns $10.35 in operating income for every $1 of interest expense ($3.6B vs $349.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$20.1B

YoY+19.9%

5Y CAGR+15.2%

10Y CAGR+9.5%

Boston Scien Cp generated $20.1B in revenue in fiscal year 2025. This represents an increase of 19.9% from the prior year.

EBITDA

$5.0B

YoY+28.6%

5Y CAGR+36.7%

10Y CAGR+26.2%

Boston Scien Cp's EBITDA was $5.0B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 28.6% from the prior year.

Net Income

$2.9B

YoY+56.7%

Boston Scien Cp reported $2.9B in net income in fiscal year 2025. This represents an increase of 56.7% from the prior year.

EPS (Diluted)

$1.94

YoY+55.2%

Boston Scien Cp earned $1.94 per diluted share (EPS) in fiscal year 2025. This represents an increase of 55.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$3.7B

YoY+38.3%

5Y CAGR+26.4%

10Y CAGR+23.5%

Boston Scien Cp generated $3.7B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 38.3% from the prior year.

Cash & Debt

$2.0B

YoY+374.6%

5Y CAGR+2.5%

10Y CAGR+19.9%

Boston Scien Cp held $2.0B in cash against $11.1B in long-term debt as of fiscal year 2025.

Shares Outstanding

1.48B

YoY+0.5%

5Y CAGR+0.9%

10Y CAGR+1.0%

Boston Scien Cp had 1.48B shares outstanding in fiscal year 2025. This represents an increase of 0.5% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

69.0%

YoY+0.4pp

5Y CAGR+4.0pp

10Y CAGR+3.3pp

Boston Scien Cp's gross margin was 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.

Operating Margin

18.0%

YoY+2.5pp

5Y CAGR+18.8pp

10Y CAGR+21.5pp

Boston Scien Cp's operating margin was 18.0% in fiscal year 2025, reflecting core business profitability. This is up 2.5 percentage points from the prior year.

Net Margin

14.4%

YoY+3.4pp

5Y CAGR+15.2pp

10Y CAGR+17.4pp

Boston Scien Cp's net profit margin was 14.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 3.4 percentage points from the prior year.

Return on Equity

11.9%

YoY+3.5pp

5Y CAGR+12.5pp

10Y CAGR+15.7pp

Boston Scien Cp's ROE was 11.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 3.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$2.1B

YoY+27.1%

5Y CAGR+12.4%

10Y CAGR+8.9%

Boston Scien Cp invested $2.1B in research and development in fiscal year 2025. This represents an increase of 27.1% from the prior year.

Capital Expenditures

$876.0M

YoY+10.9%

5Y CAGR+18.4%

10Y CAGR+13.5%

Boston Scien Cp invested $876.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 10.9% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

BSX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BSX annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$21.0B	$20.1B+19.9%	$16.7B+17.6%	$14.2B+12.3%	$12.7B+6.7%	$11.9B+19.9%	$9.9B-7.7%	$10.7B+9.3%	$9.8B+8.6%	$9.0B-0.3%	$9.1B+12.5%	$8.1B+8.1%	$7.5B+5.5%	$7.1B+1.6%	$7.0B-8.7%	$7.6B
Cost of Revenue	$6.3B	$6.2B+18.3%	$5.3B+21.0%	$4.3B+9.8%	$4.0B+6.6%	$3.7B+7.1%	$3.5B+11.2%	$3.1B+10.8%	$2.8B+8.5%	$2.6B+7.0%	$2.4B+11.6%	$2.2B-1.7%	$2.2B+1.7%	$2.2B-7.4%	$2.3B-11.7%	$2.7B
Gross Profit	$14.7B	$13.9B+20.6%	$11.5B+16.1%	$9.9B+13.4%	$8.7B+6.7%	$8.2B+26.8%	$6.4B-15.4%	$7.6B+8.7%	$7.0B+8.6%	$6.5B+8.3%	$6.0B+12.4%	$5.3B+2.6%	$5.2B+4.0%	$5.0B+1.4%	$4.9B-1.3%	$5.0B
R&D Expenses	$2.2B	$2.1B+27.1%	$1.6B+14.2%	$1.4B+6.9%	$1.3B+9.9%	$1.2B+5.3%	$1.1B-2.6%	$1.2B+5.5%	$1.1B+11.6%	$997.0M+8.4%	$920.0M+5.0%	$876.0M+7.2%	$817.0M-5.1%	$861.0M-2.8%	$886.0M-1.0%	$895.0M
SG&A Expenses	$7.2B	$6.9B+15.1%	$6.0B+15.3%	$5.2B+14.8%	$4.5B+3.7%	$4.4B+15.1%	$3.8B-3.9%	$3.9B+10.4%	$3.6B+8.3%	$3.3B+6.3%	$3.1B+7.9%	$2.9B-1.0%	$2.9B+8.5%	$2.7B+5.5%	$2.5B+1.9%	$2.5B
Operating Income	$4.2B	$3.6B+38.8%	$2.6B+11.1%	$2.3B+42.1%	$1.6B+37.5%	$1.2B+1598.8%	-$80.0M-105.3%	$1.5B+0.8%	$1.5B+17.2%	$1.3B+187.5%	$447.0M+258.0%	-$283.0M+6.0%	-$301.0M-350.8%	$120.0M+103.1%	-$3.9B-527.9%	$904.0M
Interest Expense	$363.0M	$349.0M+14.4%	$305.0M+15.1%	$265.0M-43.6%	$470.0M+37.8%	$341.0M-5.5%	$361.0M-23.7%	$473.0M+96.3%	$241.0M+5.2%	$229.0M-1.7%	$233.0M-18.0%	$284.0M+31.5%	$216.0M-33.3%	$324.0M+24.1%	$261.0M-7.1%	$281.0M
Income Tax	$193.0M	$493.0M+13.1%	$436.0M+10.9%	$393.0M-11.3%	$443.0M+1130.6%	$36.0M+1700.0%	$2.0M+100.0%	-$4.0B-1511.6%	-$249.0M-130.1%	$828.0M+587.1%	-$170.0M+58.6%	-$411.0M-5.4%	-$390.0M-282.4%	-$102.0M-161.5%	-$39.0M-119.4%	$201.0M
Net Income	$3.7B	$2.9B+56.7%	$1.8B+16.0%	$1.6B+128.1%	$698.0M-32.9%	$1.0B+1369.5%	-$82.0M-101.7%	$4.7B+181.3%	$1.7B+1506.7%	$104.0M-70.0%	$347.0M+245.2%	-$239.0M-100.8%	-$119.0M+1.7%	-$121.0M+97.0%	-$4.1B-1022.4%	$441.0M
EPS (Diluted)	—	$1.94+55.2%	$1.25+16.8%	$1.07+137.8%	$0.45-34.8%	$0.69+962.5%	-$0.08-102.4%	$3.33+179.8%	$1.19+1387.5%	$0.08-68.0%	$0.25+238.9%	-$0.18-100.0%	-$0.090.0%	-$0.09+96.9%	-$2.89-1096.6%	$0.29

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$5.4B+4.6%	$5.2B-1.6%	$5.3B+4.3%	$5.1B+0.1%	$5.1B+8.5%	$4.7B+2.2%	$4.6B+8.4%	$4.2B
Cost of Revenue	$1.6B+0.3%	$1.6B-1.1%	$1.6B+5.6%	$1.5B-7.0%	$1.6B+12.7%	$1.5B-0.9%	$1.5B+11.7%	$1.3B
Gross Profit	$3.8B+6.5%	$3.6B-1.7%	$3.7B+3.8%	$3.5B+3.4%	$3.4B+6.7%	$3.2B+3.7%	$3.1B+6.8%	$2.9B
R&D Expenses	$554.0M+7.4%	$516.0M-9.3%	$569.0M+10.7%	$514.0M-2.3%	$526.0M+18.7%	$443.0M-3.5%	$459.0M+12.8%	$407.0M
SG&A Expenses	$1.8B+1.2%	$1.8B-2.8%	$1.8B+5.3%	$1.7B+1.5%	$1.7B+7.5%	$1.6B-0.9%	$1.6B+3.2%	$1.6B
Operating Income	$1.2B+7.0%	$1.1B+33.5%	$825.0M-21.3%	$1.0B+28.0%	$819.0M-11.1%	$921.0M+36.4%	$675.0M-7.9%	$733.0M
Interest Expense	$96.0M+6.7%	$90.0M0.0%	$90.0M+3.4%	$87.0M-3.3%	$90.0M+9.8%	$82.0M+2.5%	$80.0M+1.3%	$79.0M
Income Tax	$155.0M+188.1%	-$176.0M-667.7%	$31.0M-83.1%	$183.0M+25.3%	$146.0M+9.8%	$133.0M+478.3%	$23.0M-88.5%	$200.0M
Net Income	$905.0M-32.4%	$1.3B+99.9%	$670.0M-11.3%	$755.0M-5.0%	$795.0M+18.3%	$672.0M+19.4%	$563.0M+20.3%	$468.0M
EPS (Diluted)	$0.61-32.2%	$0.90	N/A	$0.51-3.8%	$0.53+17.8%	$0.45	N/A	$0.32

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

BSX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BSX annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$43.7B+10.9%	$39.4B+12.1%	$35.1B+8.2%	$32.5B+0.7%	$32.2B+4.7%	$30.8B+0.7%	$30.6B+45.6%	$21.0B+10.3%	$19.0B+5.2%	$18.1B-0.2%	$18.1B+6.5%	$17.0B+2.7%	$16.6B-3.4%	$17.2B-19.4%	$21.3B
Current Assets	$8.8B+27.1%	$6.9B+6.2%	$6.5B+13.1%	$5.8B-8.8%	$6.3B-5.6%	$6.7B+42.5%	$4.7B+17.4%	$4.0B+4.7%	$3.8B+18.0%	$3.2B-6.7%	$3.5B-3.7%	$3.6B+19.8%	$3.0B-0.4%	$3.0B-2.7%	$3.1B
Cash & Equivalents	$2.0B+374.6%	$414.0M-52.1%	$865.0M-6.8%	$928.0M-51.8%	$1.9B+11.0%	$1.7B+699.1%	$217.0M+48.6%	$146.0M-22.3%	$188.0M-4.1%	$196.0M-38.6%	$319.0M-45.7%	$587.0M+170.5%	$217.0M+4.8%	$207.0M-22.5%	$267.0M
Inventory	$2.9B+4.7%	$2.8B+13.1%	$2.5B+33.0%	$1.9B+16.0%	$1.6B+19.2%	$1.4B-14.4%	$1.6B+35.4%	$1.2B+8.2%	$1.1B+12.9%	$955.0M-6.0%	$1.0B+7.4%	$946.0M+5.5%	$897.0M+1.5%	$884.0M-5.0%	$931.0M
Goodwill	$18.3B+7.0%	$17.1B+18.8%	$14.4B+11.4%	$12.9B+7.8%	$12.0B+20.5%	$10.0B-2.2%	$10.2B+28.6%	$7.9B+13.0%	$7.0B+4.8%	$6.7B+3.2%	$6.5B+9.7%	$5.9B+3.6%	$5.7B-4.7%	$6.0B-38.8%	$9.8B
Total Liabilities	$19.4B+10.3%	$17.6B+11.2%	$15.9B+6.4%	$14.9B-4.6%	$15.6B+1.0%	$15.5B-7.4%	$16.7B+36.0%	$12.3B+2.0%	$12.0B+5.9%	$11.4B-3.8%	$11.8B+11.8%	$10.6B+5.3%	$10.0B-2.5%	$10.3B+3.5%	$9.9B
Current Liabilities	$5.4B-15.0%	$6.4B+29.7%	$4.9B+29.7%	$3.8B-11.0%	$4.3B+16.1%	$3.7B-24.4%	$4.9B-7.5%	$5.3B-7.0%	$5.7B+57.6%	$3.6B+47.6%	$2.4B-14.6%	$2.8B+56.0%	$1.8B+2.9%	$1.8B-1.9%	$1.8B
Long-Term Debt	$11.1B+24.2%	$9.0B+4.6%	$8.6B-3.9%	$8.9B+1.3%	$8.8B-3.6%	$9.1B+6.3%	$8.6B+78.9%	$4.8B+25.9%	$3.8B-29.6%	$5.4B-4.5%	$5.7B+47.7%	$3.8B-9.3%	$4.2B-0.4%	$4.3B-0.1%	$4.3B
Total Equity	$24.2B+11.3%	$21.8B+12.9%	$19.3B+9.7%	$17.6B+5.7%	$16.6B+8.5%	$15.3B+10.4%	$13.9B+59.0%	$8.7B+24.4%	$7.0B+4.1%	$6.7B+6.5%	$6.3B-2.1%	$6.5B-1.3%	$6.5B-4.8%	$6.9B-39.5%	$11.4B
Retained Earnings	$5.6B+108.4%	$2.7B+226.4%	$819.0M+209.2%	-$750.0M+46.1%	-$1.4B+41.5%	-$2.4B-5.5%	-$2.3B+67.6%	-$7.0B+17.1%	-$8.4B+2.2%	-$8.6B+3.9%	-$8.9B-2.7%	-$8.7B-1.4%	-$8.6B-1.4%	-$8.4B-92.9%	-$4.4B

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$45.2B+2.0%	$44.4B+1.6%	$43.7B+2.3%	$42.7B+2.8%	$41.6B+3.5%	$40.1B+1.9%	$39.4B+3.5%	$38.1B
Current Assets	$8.0B-8.2%	$8.7B-1.3%	$8.8B+9.4%	$8.0B+12.8%	$7.1B-2.9%	$7.3B+6.0%	$6.9B-21.0%	$8.8B
Cash & Equivalents	$539.0M-62.9%	$1.5B-26.1%	$2.0B+54.1%	$1.3B+138.8%	$534.0M-26.3%	$725.0M+75.1%	$414.0M-83.5%	$2.5B
Inventory	$3.2B+3.8%	$3.1B+5.9%	$2.9B+0.8%	$2.9B+2.1%	$2.9B-0.2%	$2.9B+2.0%	$2.8B+2.1%	$2.8B
Goodwill	$18.6B+0.6%	$18.5B+1.4%	$18.3B+0.4%	$18.2B+0.8%	$18.1B+4.2%	$17.3B+1.5%	$17.1B+13.7%	$15.0B
Total Liabilities	$20.3B+9.7%	$18.5B-4.9%	$19.4B+0.7%	$19.3B+0.9%	$19.1B+6.8%	$17.9B+1.7%	$17.6B+1.5%	$17.4B
Current Liabilities	$6.4B+40.6%	$4.6B-16.0%	$5.4B+2.1%	$5.3B+2.7%	$5.2B+2.6%	$5.1B-21.0%	$6.4B+8.3%	$5.9B
Long-Term Debt	$10.9B-0.7%	$11.0B-1.3%	$11.1B+0.2%	$11.1B+0.1%	$11.1B+5.5%	$10.5B+17.4%	$9.0B-2.9%	$9.2B
Total Equity	$24.9B-3.6%	$25.9B+6.7%	$24.2B+3.6%	$23.4B+4.4%	$22.4B+0.9%	$22.2B+2.0%	$21.8B+5.1%	$20.7B
Retained Earnings	$7.8B+13.1%	$6.9B+24.1%	$5.6B+13.7%	$4.9B+18.2%	$4.1B+23.8%	$3.3B+25.2%	$2.7B+26.9%	$2.1B

Not reported in any period shown, so not listed: Accounts Receivable.

BSX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BSX annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	$4.5B	$4.5B+32.0%	$3.4B+37.2%	$2.5B+64.0%	$1.5B-18.4%	$1.9B+24.0%	$1.5B-17.9%	$1.8B+492.3%	$310.0M-78.3%	$1.4B+20.6%	$1.2B+71.1%	$691.0M-45.5%	$1.3B+14.3%	$1.1B-13.3%	$1.3B+27.0%	$1.0B
Capital Expenditures	$904.0M	$876.0M+10.9%	$790.0M+11.1%	$711.0M+20.9%	$588.0M+6.1%	$554.0M+47.3%	$376.0M-18.4%	$461.0M+45.9%	$316.0M-0.9%	$319.0M-15.2%	$376.0M+52.2%	$247.0M-4.6%	$259.0M+5.7%	$245.0M+8.4%	$226.0M-25.7%	$304.0M
Free Cash Flow	$3.6B	$3.7B+38.3%	$2.6B+47.6%	$1.8B+91.0%	$938.0M-28.7%	$1.3B+16.3%	$1.1B-17.7%	$1.4B+23016.7%	-$6.0M-100.5%	$1.1B+37.3%	$806.0M+81.5%	$444.0M-56.0%	$1.0B+16.8%	$865.0M-17.9%	$1.1B+49.7%	$704.0M
Investing Cash Flow	-$3.6B	-$2.6B+53.6%	-$5.7B-120.9%	-$2.6B-28.0%	-$2.0B-25.9%	-$1.6B-288.6%	-$411.0M+91.8%	-$5.0B-162.4%	-$1.9B-90.2%	-$1.0B-13.9%	-$887.0M+59.4%	-$2.2B-193.4%	-$745.0M-56.8%	-$475.0M+18.0%	-$579.0M-174.6%	$776.0M
Financing Cash Flow	-$958.0M	-$395.0M-121.8%	$1.8B+36180.0%	$5.0M+100.9%	-$548.0M-476.8%	-$95.0M-132.4%	$293.0M-90.1%	$3.0B+107.6%	$1.4B+1201.8%	$110.0M+153.4%	-$206.0M-116.1%	$1.3B+950.7%	-$150.0M+76.0%	-$624.0M+18.3%	-$764.0M+55.8%	-$1.7B
Dividends Paid	N/A	N/A	$0-100.0%	$28.0M-49.1%	$55.0M0.0%	$55.0M+96.4%	$28.0M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0	$0-100.0%	$535.0M	$0	$0	N/A	$0	$0-100.0%	$125.0M-75.0%	$500.0M-16.7%	$600.0M+22.0%	$492.0M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$1.5B+323.6%	$348.0M-74.5%	$1.4B+1.6%	$1.3B+4.4%	$1.3B+137.7%	$541.0M-62.8%	$1.5B+45.3%	$1.0B
Capital Expenditures	$195.0M+10.2%	$177.0M-49.6%	$351.0M+93.9%	$181.0M+15.3%	$157.0M-16.0%	$187.0M-32.5%	$277.0M+54.7%	$179.0M
Free Cash Flow	$1.3B+648.0%	$171.0M-83.1%	$1.0B-12.8%	$1.2B+2.9%	$1.1B+218.9%	$354.0M-70.0%	$1.2B+43.3%	$823.0M
Investing Cash Flow	-$2.0B-231.0%	-$591.0M-15.4%	-$512.0M-2.0%	-$502.0M+55.4%	-$1.1B-125.2%	-$500.0M+86.5%	-$3.7B-159.6%	-$1.4B
Financing Cash Flow	-$410.0M-57.7%	-$260.0M-41.3%	-$184.0M-76.9%	-$104.0M+69.4%	-$340.0M-245.9%	$233.0M+8.9%	$214.0M+2957.1%	$7.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0

BSX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BSX annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	69.0%+0.4pp	68.6%-0.9pp	69.5%+0.7pp	68.8%0.0pp	68.8%+3.7pp	65.0%-5.9pp	71.0%-0.4pp	71.4%0.0pp	71.3%+5.6pp	65.7%0.0pp	65.7%-3.5pp	69.3%-1.0pp	70.3%-0.2pp	70.4%+5.3pp	65.1%
Operating Margin	18.0%+2.5pp	15.5%-0.9pp	16.4%+3.5pp	13.0%+2.9pp	10.1%+10.9pp	-0.8%-14.9pp	14.1%-1.2pp	15.3%+1.1pp	14.2%+9.3pp	4.9%+8.4pp	-3.5%+0.5pp	-4.0%-5.7pp	1.7%+57.3pp	-55.6%-67.5pp	11.9%
Net Margin	14.4%+3.4pp	11.0%-0.2pp	11.2%+5.7pp	5.5%-3.3pp	8.8%+9.6pp	-0.8%-44.6pp	43.8%+26.8pp	17.0%+15.9pp	1.1%-2.7pp	3.8%+6.8pp	-3.0%-1.4pp	-1.6%+0.1pp	-1.7%+56.8pp	-58.5%-64.3pp	5.8%
Return on Equity	11.9%+3.5pp	8.5%+0.2pp	8.3%+4.3pp	4.0%-2.3pp	6.3%+6.8pp	-0.5%-34.4pp	33.9%+14.7pp	19.1%+17.7pp	1.5%-3.7pp	5.1%+8.9pp	-3.8%-1.9pp	-1.8%0.0pp	-1.8%+57.4pp	-59.2%-63.1pp	3.9%
Return on Assets	6.6%+1.9pp	4.7%+0.2pp	4.5%+2.4pp	2.1%-1.1pp	3.2%+3.5pp	-0.3%-15.7pp	15.4%+7.4pp	8.0%+7.4pp	0.5%-1.4pp	1.9%+3.2pp	-1.3%-0.6pp	-0.7%0.0pp	-0.7%+23.0pp	-23.7%-25.8pp	2.1%
Current Ratio	1.62+0.5x	1.08-0.2x	1.32-0.2x	1.510.0x	1.48-0.3x	1.82+0.9x	0.97+0.2x	0.76+0.1x	0.68-0.2x	0.90-0.5x	1.43+0.2x	1.27-0.4x	1.65-0.1x	1.710.0x	1.72
Debt-to-Equity	0.460.0x	0.410.0x	0.44-0.1x	0.510.0x	0.53-0.1x	0.600.0x	0.62+0.1x	0.550.0x	0.54-0.3x	0.81-0.1x	0.90+0.3x	0.59-0.1x	0.650.0x	0.62+0.2x	0.38
FCF Margin	18.2%+2.4pp	15.8%+3.2pp	12.6%+5.2pp	7.4%-3.7pp	11.1%-0.3pp	11.4%-1.4pp	12.8%+12.9pp	-0.1%-12.3pp	12.2%+3.4pp	8.9%+3.4pp	5.5%-8.0pp	13.5%+1.3pp	12.2%-2.9pp	15.2%+5.9pp	9.2%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	70.7%+1.2pp	69.5%-0.1pp	69.6%-0.3pp	69.9%+2.3pp	67.7%-1.2pp	68.8%+1.0pp	67.8%-1.0pp	68.8%
Operating Margin	21.6%+0.5pp	21.2%+5.6pp	15.6%-5.1pp	20.7%+4.5pp	16.2%-3.6pp	19.8%+5.0pp	14.8%-2.6pp	17.4%
Net Margin	16.6%-9.1pp	25.7%+13.1pp	12.7%-2.2pp	14.9%-0.8pp	15.7%+1.3pp	14.4%+2.1pp	12.3%+1.2pp	11.1%
Return on Equity	3.6%-1.6pp	5.2%+2.4pp	2.8%-0.5pp	3.2%-0.3pp	3.5%+0.5pp	3.0%+0.4pp	2.6%+0.3pp	2.3%
Return on Assets	2.0%-1.0pp	3.0%+1.5pp	1.5%-0.2pp	1.8%-0.1pp	1.9%+0.2pp	1.7%+0.2pp	1.4%+0.2pp	1.2%
Current Ratio	1.24-0.7x	1.90+0.3x	1.62+0.1x	1.51+0.1x	1.37-0.1x	1.45+0.4x	1.08-0.4x	1.48
Debt-to-Equity	0.440.0x	0.420.0x	0.460.0x	0.480.0x	0.500.0x	0.47+0.1x	0.410.0x	0.45
FCF Margin	23.5%+20.2pp	3.3%-15.9pp	19.2%-3.8pp	22.9%+0.6pp	22.3%+14.7pp	7.6%-18.3pp	25.8%+6.3pp	19.6%

Similar Companies

Stryker Corp SYK

$127.1B

Medtronic MDT

$117.9B

Edwards Lifesciences Corp EW

$52.4B

Abbott Labs ABT

$195.0B

Koninklijke Phil PHG

$26.5B

Where Boston Scien Cp Ranks

Frequently Asked Questions

What is Boston Scien Cp's annual revenue?

Boston Scien Cp (BSX) reported $20.1B in total revenue for fiscal year 2025. This represents a 19.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Boston Scien Cp's revenue growing?

Boston Scien Cp (BSX) revenue grew by 19.9% year-over-year, from $16.7B to $20.1B in fiscal year 2025.

Is Boston Scien Cp profitable?

Yes, Boston Scien Cp (BSX) reported a net income of $2.9B in fiscal year 2025, with a net profit margin of 14.4%.

What is Boston Scien Cp's EBITDA?

Boston Scien Cp (BSX) had EBITDA of $5.0B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Boston Scien Cp have?

As of fiscal year 2025, Boston Scien Cp (BSX) had $2.0B in cash and equivalents against $11.1B in long-term debt.

What is Boston Scien Cp's gross margin?

Boston Scien Cp (BSX) had a gross margin of 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Boston Scien Cp's operating margin?

Boston Scien Cp (BSX) had an operating margin of 18.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Boston Scien Cp's net profit margin?

Boston Scien Cp (BSX) had a net profit margin of 14.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Boston Scien Cp's return on equity (ROE)?

Boston Scien Cp (BSX) has a return on equity of 11.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Boston Scien Cp's free cash flow?

Boston Scien Cp (BSX) generated $3.7B in free cash flow during fiscal year 2025. This represents a 38.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Boston Scien Cp's operating cash flow?

Boston Scien Cp (BSX) generated $4.5B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Boston Scien Cp's total assets?

Boston Scien Cp (BSX) had $43.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Boston Scien Cp's capital expenditures?

Boston Scien Cp (BSX) invested $876.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Boston Scien Cp spend on research and development?

Boston Scien Cp (BSX) invested $2.1B in research and development during fiscal year 2025.

How many shares does Boston Scien Cp have outstanding?

Boston Scien Cp (BSX) had 1.48B shares outstanding as of fiscal year 2025.

What is Boston Scien Cp's current ratio?

Boston Scien Cp (BSX) had a current ratio of 1.62 as of fiscal year 2025, which is generally considered healthy.

What is Boston Scien Cp's debt-to-equity ratio?

Boston Scien Cp (BSX) had a debt-to-equity ratio of 0.46 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Boston Scien Cp's return on assets (ROA)?

Boston Scien Cp (BSX) had a return on assets of 6.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Boston Scien Cp's Altman Z-Score?

Boston Scien Cp (BSX) has an Altman Z-Score of 3.33, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Boston Scien Cp's Piotroski F-Score?

Boston Scien Cp (BSX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Boston Scien Cp's earnings high quality?

Boston Scien Cp (BSX) has an earnings quality ratio of 1.57x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Boston Scien Cp cover its interest payments?

Boston Scien Cp (BSX) has an interest coverage ratio of 10.35x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Boston Scien Cp?

Boston Scien Cp (BSX) scores 64 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.